Taeyeon Lee1, Na Lu2, David T Felson3, Hyon K Choi4, Deepan S Dalal5, Yuqing Zhang1, Maureen Dubreuil6. 1. Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston. 2. Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital. 3. Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston Section of Rheumatology, Boston University School of Medicine, Boston. 4. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital. 5. Section of Rheumatology, Boston University School of Medicine, Boston. 6. Section of Rheumatology, Boston University School of Medicine, Boston VA Boston Healthcare System, USA Rheumatology Division, Boston, MA, USA mdubreui@bu.edu.
Abstract
OBJECTIVE: We aimed to examine whether the current users of specific NSAIDs have an increased risk of venous thromboembolism (VTE) among knee OA patients. METHODS: We conducted a population-based case-control study using The Health Improvement Network, a database of patient records from general practices in the UK. For every VTE case, we identified five controls matched on age, sex and calendar year of study enrolment. We used conditional logistic regression to assess the association between current use of specific NSAIDs and risk of VTE relative to remote NSAID users. RESULTS: Among knee OA patients with at least one NSAID prescription, we identified 4020 incident cases of VTE and 20 059 matched controls. Adjusted odd ratios (ORs) relative to the remote users were 1.38 (95% CI: 1.32, 1.44) for recent users and 1.43 (95% CI: 1.36, 1.49) for current users. Among the current NSAID users, the risk of VTE was increased with diclofenac [OR 1.63 (95% CI: 1.53, 1.74)], ibuprofen [OR = 1.49 (95% CI: 1.38, 1.62)], meloxicam [OR = 1.29 (95% CI: 1.11, 1.50)] and coxibs [celecoxib, OR = 1.30 (95% CI: 1.11, 1.51); rofecoxib, OR = 1.44 (95% CI: 1.18, 1.76)]; naproxen did not increase VTE risk [OR = 1.00 (95% CI: 0.89, 1.12)]. CONCLUSION: Compared with the remote users of NSAIDs, the risk of VTE increased for current users of diclofenac, ibuprofen, meloxicam, and coxibs, but not for naproxen, in the knee OA population. Clinicians should consider the risk profile for specific NSAIDs when recommending their use.
OBJECTIVE: We aimed to examine whether the current users of specific NSAIDs have an increased risk of venous thromboembolism (VTE) among knee OA patients. METHODS: We conducted a population-based case-control study using The Health Improvement Network, a database of patient records from general practices in the UK. For every VTE case, we identified five controls matched on age, sex and calendar year of study enrolment. We used conditional logistic regression to assess the association between current use of specific NSAIDs and risk of VTE relative to remote NSAID users. RESULTS: Among knee OA patients with at least one NSAID prescription, we identified 4020 incident cases of VTE and 20 059 matched controls. Adjusted odd ratios (ORs) relative to the remote users were 1.38 (95% CI: 1.32, 1.44) for recent users and 1.43 (95% CI: 1.36, 1.49) for current users. Among the current NSAID users, the risk of VTE was increased with diclofenac [OR 1.63 (95% CI: 1.53, 1.74)], ibuprofen [OR = 1.49 (95% CI: 1.38, 1.62)], meloxicam [OR = 1.29 (95% CI: 1.11, 1.50)] and coxibs [celecoxib, OR = 1.30 (95% CI: 1.11, 1.51); rofecoxib, OR = 1.44 (95% CI: 1.18, 1.76)]; naproxen did not increase VTE risk [OR = 1.00 (95% CI: 0.89, 1.12)]. CONCLUSION: Compared with the remote users of NSAIDs, the risk of VTE increased for current users of diclofenac, ibuprofen, meloxicam, and coxibs, but not for naproxen, in the knee OA population. Clinicians should consider the risk profile for specific NSAIDs when recommending their use.
Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: Sara Biere-Rafi; Marcello Di Nisio; Victor Gerdes; Ettore Porreca; Patrick Souverein; Anthonius Boer; Harry Büller; Pieter Kamphuisen Journal: Pharmacoepidemiol Drug Saf Date: 2011-06 Impact factor: 2.890
Authors: Félix M Arellano; Marianne Ulcickas Yood; Charles E Wentworth; Susan A Oliveria; Elena Rivero; Anila Verma; Kenneth J Rothman Journal: Pharmacoepidemiol Drug Saf Date: 2006-12 Impact factor: 2.890
Authors: Giovanni Corrao; Arianna Ghirardi; Giulia Segafredo; Antonella Zambon; Gianluca Della Vedova; Francesco Lapi; Francesco Cipriani; Achille Caputi; Alberto Vaccheri; Dario Gregori; Rosaria Gesuita; Annarita Vestri; Tommaso Staniscia; Giampiero Mazzaglia; Mauro Di Bari Journal: Pharmacoepidemiol Drug Saf Date: 2014-06-09 Impact factor: 2.890
Authors: Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič Journal: Eur J Clin Pharmacol Date: 2019-02-05 Impact factor: 2.953
Authors: Joseph Purita; José Fábio Santos Duarte Lana; Morey Kolber; Bruno Lima Rodrigues; Tomas Mosaner; Gabriel Silva Santos; Carolina Caliari-Oliveira; Stephany Cares Huber Journal: World J Stem Cells Date: 2020-04-26 Impact factor: 5.326
Authors: Tracy L Kinsey; Til Stürmer; Michele Jonsson Funk; Charles Poole; Ross J Simpson; Robert J Glynn Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580
Authors: Tiffanie-Marie Borg; Nima Heidari; Ali Noorani; Mark Slevin; Angela Cullen; Stefano Olgiati; Alberto Zerbi; Alessandro Danovi; Adrian Wilson Journal: Stem Cells Int Date: 2021-02-25 Impact factor: 5.443
Authors: Peter Nash; Andreas Kerschbaumer; Thomas Dörner; Maxime Dougados; Roy M Fleischmann; Klaus Geissler; Iain McInnes; Janet E Pope; Désirée van der Heijde; Michaela Stoffer-Marx; Tsutomu Takeuchi; Michael Trauner; Kevin L Winthrop; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Wolf-Henning Boehncke; Paul Emery; John D Isaacs; Joel Kremer; Eun Bong Lee; Walter P Maksymowych; Marieke Voshaar; Lai-Shan Tam; Yoshiya Tanaka; Filip van den Bosch; René Westhovens; Ricardo Xavier; Josef S Smolen Journal: Ann Rheum Dis Date: 2020-11-06 Impact factor: 19.103